OutSmart Cancer - Precision Oncology. Less Guess Work. More Life!
OutSmart Cancer is the podcast for people who refuse to settle for one-size-fits-all cancer care. Hosted by Dr. Dino Prato, founder of Envita Medical Centers, this show offers expert insight into the world of precision oncology, integrative treatments, and the hidden factors that make cancer so hard to treat — and what to do about them.
Whether you’ve been newly diagnosed, are navigating treatment resistance, or want a second opinion grounded in science and compassion, you’ll hear empowering discussions on:
- DNA, RNA, and immune-based targeting
- The truth behind standard protocols
- What most doctors miss in treatment planning
- Stories of hope from patients who’ve been told “there’s nothing more we can do”
We believe in personalized, data-driven medicine — not protocol-based guessing.
You don’t have to fight cancer blindly. You can OutSmart it.
Disclaimer: This podcast is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before making medical decisions. Results vary and no specific outcomes are guaranteed. Some treatments may not be FDA-approved or available in all locations. Testimonials reflect individual experiences and may not represent typical outcomes. Certain therapies may be offered only at Envita’s international clinic in Hermosillo, Mexico.
OutSmart Cancer - Precision Oncology. Less Guess Work. More Life!
How Do Tumors Hide From Treatment?
Why do so many cancers resist treatment — even when patients receive the strongest chemotherapy available?
In this episode, Dr. Dino Prato, founder of Envita Medical Centers, explains the “Great Wall of Cancer”: a fibrous stromal barrier that surrounds many tumors. This wall blocks chemotherapy, immunotherapy, and even the body’s own immune system from reaching the cancer.
Dr. Prato discusses how this barrier forms, why it accelerates metastasis in cancers like pancreatic, breast, stomach, colorectal, and head and neck cancers, and how Envita uses advanced testing to identify and measure it.
🎯 What You’ll Learn in This Episode:
- Why IV chemotherapy often delivers less than 5% of the drug to the tumor
- How stromal barriers weaken immune cells and push cancer to spread
- The role of spatial biology, molecular profiling, and precision testing in mapping tumor defenses
- How interventional radiology delivers medicine directly inside tumors using tiny catheters
- Why CIPI (Chemo-Immuno-Precision Injection) improves outcomes and activates the immune system
- A real case study where stage IV neuroendocrine carcinoma was successfully treated with this method
📊 In published outcomes, patients receiving these precision approaches saw significant improvements in survival and quality of life compared to standard treatments.*
*(See Outcomes Disclaimer Below)
“Cancer may build a wall — but precision oncology helps break it down.”
Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
You can read the full peer-reviewed study at:
https://www.scirp.org/journal/paperinformation?paperid=132493